Baseline characteristics of patients evaluated on the non-del(11q) treatment arms
| Variable . | FR, N = 123 . | FR+L, N = 109 . | FCR, N = 110 . | P* . |
|---|---|---|---|---|
| Median age (range), y | 61 (28-81) | 62 (36-79) | 60 (32-80) | .97 |
| Sex, n (%) | .76 | |||
| Male | 83 (67) | 69 (63) | 70 (64) | |
| Female | 40 (33) | 40 (37) | 40 (36) | |
| Rai stage, no. (%) | .98 | |||
| I | 26 (21) | 23 (21) | 23 (21) | |
| II | 40 (33) | 31 (28) | 37 (34) | |
| III | 25 (20) | 22 (20) | 21 (19) | |
| IV | 32 (26) | 33 (30) | 29 (26) | |
| ECOG PS, no. (%) | .81 | |||
| 0 | 61 (50) | 60 (55) | 60 (55) | |
| 1 | 58 (47) | 44 (40) | 47 (43) | |
| 2 | 4 (3) | 5 (5) | 3 (3) | |
| Median hemoglobin (range), g/L | 128 (59-161) | 120 (59-162) | 119 (69-173) | .18 |
| Median platelets (range), ×109/L | 151 (48-486) | 133 (24-410) | 133 (12-303) | .46 |
| Median WBC (range), ×109/L | 72.9 (2.2-424.9) | 92.6 (6.2-476.9) | 80.8 (1.2-899.8) | .52 |
| B2M above normal, no. (%) | .79 | |||
| No | 22 (18) | 16 (15) | 17 (16) | |
| Yes | 97 (82) | 89 (85) | 87 (84) | |
| LDH above normal, no. (%) | .07 | |||
| No | 57 (46) | 64 (59) | 48 (44) | |
| Yes | 66 (54) | 45 (41) | 60 (56) | |
| Serum creatinine above normal, no. (%) | .44 | |||
| No | 109 (90) | 100 (92) | 95 (86) | |
| Yes | 12 (10) | 9 (8) | 15 (14) | |
| Palpable splenomegaly, no. (%) | .37 | |||
| No | 71 (60) | 56 (52) | 55 (51) | |
| Yes | 48 (40) | 52 (48) | 52 (49) | |
| Palpable hepatomegaly, no. (%) | .005 | |||
| No | 116 (98) | 98 (94) | 93 (88) | |
| Yes | 2 (2) | 6 (6) | 13 (12) | |
| Adenopathy, no. (%) | .50 | |||
| No adenopathy | 4 (3) | 2 (2) | 3 (3) | |
| Yes, lymph node <5cm | 80 (70) | 74 (72) | 80 (74) | |
| Yes, lymph node 5-10cm | 24 (21) | 23 (22) | 15 (14) | |
| Yes, lymph node >10cm | 7 (6) | 4 (4) | 10 (9) | |
| del(17p), no. (%) | .90 | |||
| Absent | 106 (89) | 92 (91) | 96 (90) | |
| Present | 13 (11) | 9 (9) | 11 (10) | |
| del(11q),†no. (%) | .92 | |||
| Absent | 111 (93) | 94 (93) | 101 (94) | |
| Present | 8 (7) | 7 (7) | 6 (6) | |
| Trisomy 12, no. (%) | .30 | |||
| Absent | 90 (76) | 79 (78) | 74 (69) | |
| Present | 29 (24) | 22 (22) | 33 (31) | |
| del(13q), no. (%) | .14 | |||
| Absent | 60 (50) | 39 (39) | 54 (50) | |
| Present | 59 (50) | 62 (61) | 53 (50) | |
| Hierarchical cytogenetic classification, no. (%) | .56 | |||
| del(17p) | 13 (11) | 9 (9) | 11 (10) | |
| del(11q) | 7 (6) | 6 (6) | 4 (4) | |
| Trisomy 12 | 25 (21) | 20 (20) | 31 (29) | |
| None | 23 (19) | 19 (19) | 26 (24) | |
| del(13q) | 51 (43) | 47 (47) | 35 (33) |
| Variable . | FR, N = 123 . | FR+L, N = 109 . | FCR, N = 110 . | P* . |
|---|---|---|---|---|
| Median age (range), y | 61 (28-81) | 62 (36-79) | 60 (32-80) | .97 |
| Sex, n (%) | .76 | |||
| Male | 83 (67) | 69 (63) | 70 (64) | |
| Female | 40 (33) | 40 (37) | 40 (36) | |
| Rai stage, no. (%) | .98 | |||
| I | 26 (21) | 23 (21) | 23 (21) | |
| II | 40 (33) | 31 (28) | 37 (34) | |
| III | 25 (20) | 22 (20) | 21 (19) | |
| IV | 32 (26) | 33 (30) | 29 (26) | |
| ECOG PS, no. (%) | .81 | |||
| 0 | 61 (50) | 60 (55) | 60 (55) | |
| 1 | 58 (47) | 44 (40) | 47 (43) | |
| 2 | 4 (3) | 5 (5) | 3 (3) | |
| Median hemoglobin (range), g/L | 128 (59-161) | 120 (59-162) | 119 (69-173) | .18 |
| Median platelets (range), ×109/L | 151 (48-486) | 133 (24-410) | 133 (12-303) | .46 |
| Median WBC (range), ×109/L | 72.9 (2.2-424.9) | 92.6 (6.2-476.9) | 80.8 (1.2-899.8) | .52 |
| B2M above normal, no. (%) | .79 | |||
| No | 22 (18) | 16 (15) | 17 (16) | |
| Yes | 97 (82) | 89 (85) | 87 (84) | |
| LDH above normal, no. (%) | .07 | |||
| No | 57 (46) | 64 (59) | 48 (44) | |
| Yes | 66 (54) | 45 (41) | 60 (56) | |
| Serum creatinine above normal, no. (%) | .44 | |||
| No | 109 (90) | 100 (92) | 95 (86) | |
| Yes | 12 (10) | 9 (8) | 15 (14) | |
| Palpable splenomegaly, no. (%) | .37 | |||
| No | 71 (60) | 56 (52) | 55 (51) | |
| Yes | 48 (40) | 52 (48) | 52 (49) | |
| Palpable hepatomegaly, no. (%) | .005 | |||
| No | 116 (98) | 98 (94) | 93 (88) | |
| Yes | 2 (2) | 6 (6) | 13 (12) | |
| Adenopathy, no. (%) | .50 | |||
| No adenopathy | 4 (3) | 2 (2) | 3 (3) | |
| Yes, lymph node <5cm | 80 (70) | 74 (72) | 80 (74) | |
| Yes, lymph node 5-10cm | 24 (21) | 23 (22) | 15 (14) | |
| Yes, lymph node >10cm | 7 (6) | 4 (4) | 10 (9) | |
| del(17p), no. (%) | .90 | |||
| Absent | 106 (89) | 92 (91) | 96 (90) | |
| Present | 13 (11) | 9 (9) | 11 (10) | |
| del(11q),†no. (%) | .92 | |||
| Absent | 111 (93) | 94 (93) | 101 (94) | |
| Present | 8 (7) | 7 (7) | 6 (6) | |
| Trisomy 12, no. (%) | .30 | |||
| Absent | 90 (76) | 79 (78) | 74 (69) | |
| Present | 29 (24) | 22 (22) | 33 (31) | |
| del(13q), no. (%) | .14 | |||
| Absent | 60 (50) | 39 (39) | 54 (50) | |
| Present | 59 (50) | 62 (61) | 53 (50) | |
| Hierarchical cytogenetic classification, no. (%) | .56 | |||
| del(17p) | 13 (11) | 9 (9) | 11 (10) | |
| del(11q) | 7 (6) | 6 (6) | 4 (4) | |
| Trisomy 12 | 25 (21) | 20 (20) | 31 (29) | |
| None | 23 (19) | 19 (19) | 26 (24) | |
| del(13q) | 51 (43) | 47 (47) | 35 (33) |
Percent values are calculated out of the number of patients with nonmissing data in each category.
B2M, β-2 microglobulin; ECOG PS indicates Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; WBC, white blood cell count.
χ2 or Fisher’s exact and Kruskal-Wallis P values are presented for categoric and continuous variables, respectively.
The del(11q) category includes patients with del(11q) detected in >2.3% of cells (above background) and in <20% of cells.